open access

Vol 6 (2021): Continuous Publishing
Case report
Published online: 2021-10-13
Get Citation

Treatment of heterophoria with botulinum toxin A — a case study

Przemysław Raczkiewicz1, Barbara Biziorek2
·
Ophthalmol J 2021;6:151-154.
Affiliations
  1. Student Research Group at the Clinic and Department of General and Children's Ophthalmology of the Medical University of Lublin, Lublin, Poland
  2. OCHO — Eye Surgery Center, Nałęczów, Poland

open access

Vol 6 (2021): Continuous Publishing
CASE REPORTS
Published online: 2021-10-13

Abstract

Background: Heterophoria (latent strabismus) is an imbalance in the tone of the oculomotor muscles. In a young child, this disorder usually does not affect the development of binocular vision. While looking, binocular vision (image fusion) keeps the eyeballs straight. With age, binocular vision may be impaired, for example, as a result of trauma, general disease, stress, or severe fatigue, and thus strabismus (heterotopia) may be revealed, which causes double vision. The patient, in our case, developed diplopia as a result of stress and fatigue.

Case presentation: The patient underwent treatment with the use of botulinum toxin A. After each procedure, an ophthalmological examination was performed to measure the strabismus angle. Three courses of botulinum toxin A injection reduced the strabismus angle by 86%, the double vision passed.

Conclusions: The case shows the possibility of curing an adult with Botulinum toxin A, in whom latent strabismus has turned into esotropia. Despite its transient kinetics, botulinum toxin A can have a lasting effect on eye alignment, favoring binocularity and reducing double vision, and can serve as a primary treatment. To obtain a permanent result, it is necessary to repeat the treatment.

Abstract

Background: Heterophoria (latent strabismus) is an imbalance in the tone of the oculomotor muscles. In a young child, this disorder usually does not affect the development of binocular vision. While looking, binocular vision (image fusion) keeps the eyeballs straight. With age, binocular vision may be impaired, for example, as a result of trauma, general disease, stress, or severe fatigue, and thus strabismus (heterotopia) may be revealed, which causes double vision. The patient, in our case, developed diplopia as a result of stress and fatigue.

Case presentation: The patient underwent treatment with the use of botulinum toxin A. After each procedure, an ophthalmological examination was performed to measure the strabismus angle. Three courses of botulinum toxin A injection reduced the strabismus angle by 86%, the double vision passed.

Conclusions: The case shows the possibility of curing an adult with Botulinum toxin A, in whom latent strabismus has turned into esotropia. Despite its transient kinetics, botulinum toxin A can have a lasting effect on eye alignment, favoring binocularity and reducing double vision, and can serve as a primary treatment. To obtain a permanent result, it is necessary to repeat the treatment.

Get Citation

Keywords

strabismus; botulinum toxin A; esotropia

About this article
Title

Treatment of heterophoria with botulinum toxin A — a case study

Journal

Ophthalmology Journal

Issue

Vol 6 (2021): Continuous Publishing

Article type

Case report

Pages

151-154

Published online

2021-10-13

Page views

6345

Article views/downloads

510

DOI

10.5603/OJ.2021.0022

Bibliographic record

Ophthalmol J 2021;6:151-154.

Keywords

strabismus
botulinum toxin A
esotropia

Authors

Przemysław Raczkiewicz
Barbara Biziorek

References (15)
  1. Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev. 2017; 3: CD006499.
  2. Gunton KB, Wasserman BN, DeBenedictis C. Strabismus. Prim Care. 2015; 42(3): 393–407.
  3. Cunningham ET, Riordan-Eva P. Vaughan & Asbury's General Ophthalmology. 18th ed. McGraw-Hill Medical, Huckelberry 2011.
  4. MacEwen C, Gregson R. Manual of strabismus surgery. Butterworth-Heinemann , Oxford 2003.
  5. Docket No. FDA-2008-P-0061. Food and Drug Administration. United States Department of Health and Human Services.
  6. Thouvenin D, Lesage-Beaudon C, Arné JL. Injection de toxine botulique dans les strabismes précoces. Efficacité et incidence sur les indications chirurgicales ultérieures. J Franç Ophtalmol. 2008; 31(1): 42–50.
  7. de Alba Campomanes AG, Binenbaum G, Campomanes Eguiarte G. Comparison of botulinum toxin with surgery as primary treatment for infantile esotropia. J AAPOS. 2010; 14(2): 111–116.
  8. Mangan MS, Basar E, Mahan M, et al. Pediatric Eye Disease Investigator Group. Botulinum A toxin therapy on esotropia in children. J Med Assoc Thai. 2002; 85(11): 1189–1197.
  9. Scott AB. Change of eye muscle sarcomeres according to eye position. J Pediatr Ophthalmol Strabismus. 1994; 31(2): 85–88.
  10. Hered R. Chapter 14: Surgery for extraocular muscles. In: In: 2018-2019 Basic and Clinical Science Course, Section 06: Pediatric Ophthalmology and Strabismus. American Academy Ophthalmology, Philadelphia 2018: 241–242.
  11. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004; 19 Suppl 8: S92–S9S100.
  12. Rayner SA, Hollick EJ, Lee JP. Botulinum toxin in childhood strabismus. Strabismus. 1999; 7(2): 103–111.
  13. Scott A, Magoon E, McNeer K, et al. Botulinum Treatment of Childhood Strabismus. Ophthalmology. 1990; 97(11): 1434–1438.
  14. Lennerstrand G, Nordbø OA, Tian S, et al. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand. 1998; 76(1): 27–27.
  15. Elston JS, Lee JP, Powell CM, et al. Treatment of strabismus in adults with botulinum toxin A. Br J Ophthalmol. 1985; 69(10): 718–724.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Publisher: VM Media Group sp. z o.o., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 310 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl